home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

International Congress of Antibodies

 
  October 28, 2009  
     
 
BIT, Beijing, China
2010.3.24-26


Track 1: Scientific Basis and Emerging Technologies for Antibodies
Track 2: Researches on Antibody Molecular Targets of Cancers
Track 3:Targeting Therapeutic Monoclonal Antibody R & D for Major Cancers
Track 4: Therapeutic MAbs for Infection Diseases
Track 5: Therapeutic MAbs for CNS Diseases
Track 6: Therapeutic MAbs for Inflammatory and Autoimmune Diseases
Track 7: Therapeutic MAbs for Other Non-Cancer/Non-Infective Diseases
Track 8: Preclinical /Clinical Studies of Monoclonal Therapeutics
Track 9: Antibodies and Clinical Diagnostics and Therapy
Track 10: Antibody Engineering and Production
Track 11: Bio-Venture Capital Forum on Antibodies-Financing and Business Development
Track 12: Workshops and Training Courses
 
 
Organized by: BIT
Invited Speakers: Dr. Masa Fujiwara, President&CEO, Chiome Bioscience Inc.,JapanDr. Tom Smart, Chairman & CEO, AnaptysBio, Inc., USADr. Liangzhi Xie, President and CEO, Sino Biological Inc., Professor, Peking Union Medical College, ChinaDr. Teodor Aastrup, CEO, Attana AB, SwedenDr. Timothy S. Zheng, Principal Scientist & Scientific Evaluation Liaison, Biogen Idec, Inc., UKDr. Daniel Chain, Chairman and CEO, Intellect Neurosciences, Inc., USADr. Chris Ullman, CSO, Isogenica Ltd., UKDr. Evan B. Siegel, President and CEO, Ground Zero Pharmaceuticals, Inc., USADr. Tony Warford, Discipline Leader, AstraZeneca, Innovation Center China, ChinaDr. Steffen Nock, Acting CEO, Arana Therapeutics, USADr. Ewa Pol, Scientist, GE Heathcare Life Sciences, SwedenDr. Andreas Baumann, Principal Scientific Expert Biologics, Bayer Schering Pharma AG, GermanyDr. Wolfgang Teschner, Director Research, Plasma Product Development / Product Support, Global Pre-clinical R&D, Baxter Innovations GmbH, GermanyDr. David Wenyan Shen, Executive Director and Head, Biologics Research & GlycoFi, Merck & Co., Inc., USA
 
Deadline for Abstracts: January 31, 2010
 
Registration: plz go to http://www.bitlifesciences.com/ica2010
E-mail: sean@bit-ica.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.